News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
249,279 Results
Type
Article (8047)
Company Profile (27)
Press Release (241201)
Section
Business (70019)
Career Advice (134)
Deals (10965)
Drug Delivery (18)
Drug Development (32893)
Employer Resources (10)
FDA (5545)
Job Trends (4835)
News (110672)
Policy (8310)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Standard (1)
2027 Genetown Premier (1)
2027 Genetown Standard (1)
2027 Pharm Country Digital (1)
2027 Pharm Country Standard (1)
Academia (736)
Accelerated approval (41)
ADA (37)
Adcomms (6)
Allergies (90)
Alliances (10639)
ALS (165)
Alzheimer's disease (974)
Antibody-drug conjugate (ADC) (388)
Approvals (6262)
Artificial intelligence (433)
ASCO (237)
Autoimmune disease (241)
Automation (38)
Bankruptcy (97)
Belgium (21)
Best Places to Work (4638)
BIO (32)
Biologics (41)
BIOSECURE Act (5)
Biosimilars (146)
BioSpace Insights (15)
Biotechnology (20)
Bispecific (37)
Bladder cancer (179)
Brain cancer (41)
Breast cancer (570)
Cancer (4534)
Cardiovascular disease (345)
Career advice (117)
CAR-T (146)
CDC (12)
CDMO (78)
Celiac Disease (3)
Cell therapy (466)
Cervical cancer (43)
Clinical research (32478)
Collaboration (1271)
Commercialization (24)
Company closure (3)
Compensation (686)
Complete response letters (20)
COVID-19 (619)
CRISPR (70)
C-suite (687)
Cystic fibrosis (92)
Data (6639)
Decentralized trials (1)
Denatured (1)
Depression (76)
Dermatology (136)
Diabetes (353)
Diagnostics (2287)
Digital health (32)
Diversity (1)
Diversity, equity & inclusion (2)
Drug discovery (192)
Drug pricing (35)
Drug shortages (3)
Duchenne muscular dystrophy (181)
Earnings (41694)
Editorial (19)
Employer resources (8)
ESMO (346)
Events (59765)
Executive appointments (603)
Eye disease (9)
FDA (8138)
Fibrodysplasia Ossificans Progressiva (10)
Fragile X (4)
Friedreich's ataxia (13)
Frontotemporal dementia (18)
Funding (958)
Gene editing (129)
Generative AI (23)
Gene therapy (356)
GLP-1 (382)
Government (1131)
Grass and pollen (4)
Guidances (262)
Healthcare (6456)
Hematology (92)
HIV (73)
Huntington's disease (32)
Idiopathic pulmonary fibrosis (7)
IgA nephropathy (94)
Immunology and inflammation (131)
Immuno-oncology (88)
Indications (173)
Infectious disease (785)
Inflammatory bowel disease (139)
Inflation Reduction Act (5)
Influenza (51)
Intellectual property (137)
Interviews (23)
IPO (6184)
IRA (6)
Job creations (521)
Job search strategy (95)
JPM (55)
Kidney cancer (19)
Kidney disease (93)
Labor market (6)
Layoffs (78)
Leadership (7)
Legal (1575)
Licensing (44)
Liver cancer (61)
Longevity (20)
Lung cancer (758)
Lung diease (11)
Lymphoma (344)
Machine learning (43)
Management (4)
Manufacturing (515)
Marketing (21)
MASH (137)
Medical affairs (4)
Medical device (4682)
Medtech (4808)
Mergers & acquisitions (5609)
Metabolic disorders (778)
mRNA (116)
Multiple sclerosis (134)
Multispecific (2)
NASH (14)
Netherlands (15)
Neurodegenerative disease (295)
Neuropsychiatric disorders (45)
Neuroscience (1967)
Neurotech (3)
NextGen: Class of 2026 (1669)
Non-profit (1355)
Now hiring (9)
Obesity (271)
Opinion (41)
Ovarian cancer (147)
Pain (153)
Pancreatic cancer (257)
Parkinson's disease (242)
Partnered (6)
Patents (248)
Patient advocacy (2)
Patient recruitment (476)
Patient selection (46)
Peanut (30)
People (14989)
Peptides (15)
Pharmaceutical (10)
Pharmacy benefit managers (8)
Phase 1 (8287)
Phase 2 (13678)
Phase 3 (12703)
Pipeline (7507)
Policy (64)
Postmarket research (1275)
Preclinical (3652)
Press Release (14)
Prostate cancer (242)
Psychedelics (14)
Radioligand (2)
Radiopharmaceuticals (160)
Rare diseases (649)
Real estate (1154)
Recruiting (4)
Regenerative medicine (13)
Regulatory (8711)
Reports (14)
Research institute (746)
Resumes & cover letters (22)
Rett syndrome (44)
RNA editing (9)
RSV (39)
Schizophrenia (101)
Series A (167)
Series B (115)
Service/supplier (3)
Sickle cell disease (74)
Special edition (7)
Spinal muscular atrophy (59)
Sponsored (20)
Startups (713)
Stem cells (3)
Stomach cancer (15)
Substance use disorders (6)
Supply chain (55)
Switzerland (3)
Tariffs (16)
The Weekly (16)
Vaccines (375)
Venture capital (45)
Weight loss (133)
Wet AMD (2)
Women's health (86)
Date
Today (73)
Last 7 days (507)
Last 30 days (1745)
Last 365 days (16586)
2026 (13817)
2025 (16461)
2024 (14781)
2023 (14986)
2022 (18227)
2021 (18974)
2020 (17879)
2019 (15091)
2018 (11318)
2017 (10180)
2016 (10044)
2015 (12655)
2014 (9367)
2013 (7176)
2012 (7933)
2011 (8373)
2010 (7289)
Location
Africa (127)
Alabama (28)
Alaska (1)
Arizona (126)
Arkansas (6)
Asia (11490)
Australia (1889)
California (9082)
Canada (1760)
China (995)
Colorado (350)
Connecticut (363)
Delaware (332)
Europe (30869)
Florida (1037)
Georgia (242)
Hawaii (4)
Idaho (18)
Illinois (782)
India (64)
Indiana (357)
Iowa (15)
Japan (523)
Kansas (33)
Kentucky (28)
Louisiana (54)
Maine (29)
Maryland (937)
Massachusetts (6362)
Michigan (170)
Minnesota (403)
Mississippi (2)
Missouri (121)
Montana (2)
Nebraska (6)
Nevada (141)
New Hampshire (35)
New Jersey (2367)
New Mexico (11)
New York (2147)
North Carolina (863)
North Dakota (6)
Northern California (4641)
Ohio (226)
Oklahoma (11)
Oregon (15)
Pennsylvania (2622)
Puerto Rico (11)
Rhode Island (16)
South America (233)
South Carolina (16)
Southern California (3695)
Tennessee (144)
Texas (1372)
United States (30896)
Utah (201)
Vermont (1)
Virginia (206)
Washington D.C. (32)
Washington State (635)
West Virginia (1)
Wisconsin (130)
249,279 Results for "amorchem l p".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Icahn Enterprises L.P. Announces Q2 2026 Earnings Conference Call
July 24, 2026
·
1 min read
Press Releases
AINN-P1: Small Model, Big Intelligence
AINN-P1: Small Model, Big IntelligenceHow does a 167M-parameter protein foundation model outperform a 650M general-purpose model on the tasks that matter?
September 10, 2026
·
1 min read
Press Releases
L7 Informatics Advocates for Neuro-Symbolic AI in Regulated Life Sciences
L7 Informatics’ position is that generative AI has been deployed in regulated science with only half the architecture it needs, and that the missing half is an active knowledge graph generated at the point of execution.
July 23, 2026
·
1 min read
Press Releases
GCAR and Purdue Pharma L.P. Announce Initiation of Tinostamustine in GBM AGILE Trial
April 8, 2026
·
6 min read
Press Releases
Inside the 98 Percent: L7 Informatics on the Operational Harness That Determines Pharma’s Agentic AI Outcomes
L7 Informatics CEO, Vasu Rangadass, Ph.D., examines the architectural principle separating pharmaceutical AI experimentation from enterprise-scale deployment.
June 12, 2026
·
1 min read
Press Releases
Lobe Sciences Appoints Tracy L. Goeken, M.D., as Chief Medical Officer
October 20, 2026
·
8 min read
Press Releases
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
October 14, 2026
·
19 min read
Press Releases
L7 Informatics Makes the Case for an Agentic Operating System as the Strategic Foundation for Regulated Process Industries
L7 CEO Vasu Rangadass, Ph.D., argues that regulated process industries have reached the limits of point-solution modernization and must pivot to unified orchestration to unlock the promise of agentic AI.
June 15, 2026
·
1 min read
Opinion
The real potential of PD-(L)1×VEGF bispecifics may be outside lung cancer
PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing through trials in lung cancer. But the potential of these drugs may be highest in cancers where angiogenesis and immune escape are tightly intertwined.
May 28, 2026
·
6 min read
·
Souro Chowdhury
Press Releases
CasZyme and Cirena to Collaborate on Developing Longer Guide RNAs to Optimise Cas12l Performance
October 26, 2026
·
2 min read
1 of 24,928
Next
